Genentech Continues Pipeline Push After Rituxan Fizzles In PPMS
Executive Summary
The failure of Genentech's Rituxan in a Phase II/III trial in primary progressive multiple sclerosis adds weight to the idea that B cells do not play a role in the disease and may cast doubt on rituximab's potential in lupus